Chartwell Partners was honored to work with HemoShear Therapeutics on the recruitment of Pat Horn as Chief Medical Officer. Based in Charlotteville, VA, HemoShear is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need. HST5040, an oral small molecule drug, is HemoShear’s lead development program and is now in early phase 2 studies for methylmalonic acidemia and propionic acidemia.
Pat joins from Albireo Pharma where he served as Chief Medical Officer since July 2018. While at the company, he led the team that achieved accelerated marketing approvals in the US and Europe for BylvayTM in progressive familial intrahepatic cholestasis (PFIC). He also designed and initiated pivotal clinical development programs in biliary atresia and Alagille syndrome. Prior to Albireo, he led clinical development programs in hereditary angioedema, homocystinuria, and infectious disease. Dr. Horn has formal training and extensive experience in clinical pharmacology. He received his MD and PhD from the University of Chicago and completed a pediatric residency at Boston Children’s Hospital. Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.
For more information, please see HemoShear’s press release – https://hemoshear.com/news/hemoshear-therapeutics-appoints-patrick-horn-md-phd-chief-medical-officer